Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. 

Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden. Vitrolife Group’s products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to enable people to fulfill the dream of having a healthy baby. 

The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.